FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:BTRC-HIF1AN

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: BTRC-HIF1AN
FusionPDB ID: 10564
FusionGDB2.0 ID: 10564
HgeneTgene
Gene symbol

BTRC

HIF1AN

Gene ID

8945

55662

Gene namebeta-transducin repeat containing E3 ubiquitin protein ligasehypoxia inducible factor 1 subunit alpha inhibitor
SynonymsBETA-TRCP|FBW1A|FBXW1|FBXW1A|FWD1|bTrCP|bTrCP1|betaTrCPFIH1
Cytomap

10q24.32

10q24.31

Type of geneprotein-codingprotein-coding
DescriptionF-box/WD repeat-containing protein 1AE3RSIkappaBF-box and WD repeats protein beta-TrCPF-box and WD-repeat protein 1Bbeta-TrCP1epididymis tissue protein Li 2apIkappaBalpha-E3 receptor subunithypoxia-inducible factor 1-alpha inhibitorFIH-1factor inhibiting HIF-1factor inhibiting HIF1hypoxia inducible factor 1 alpha subunit inhibitorhypoxia-inducible factor asparagine hydroxylasepeptide-aspartate beta-dioxygenase
Modification date2020032720200313
UniProtAcc

Q9Y297

Main function of 5'-partner protein: FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds to phosphorylated target proteins (PubMed:10066435, PubMed:10497169, PubMed:10644755, PubMed:10835356, PubMed:11238952, PubMed:11359933, PubMed:11994270, PubMed:12791267, PubMed:12902344, PubMed:14603323, PubMed:14681206, PubMed:14988407, PubMed:15448698, PubMed:15917222, PubMed:16371461, PubMed:25503564, PubMed:25704143, PubMed:9859996, PubMed:22087322). SCF(BTRC) mediates the ubiquitination of CTNNB1 and participates in Wnt signaling (PubMed:12077367, PubMed:12820959). SCF(BTRC) mediates the ubiquitination of phosphorylated NFKB1, ATF4, CDC25A, DLG1, FBXO5, PER1, SMAD3, SMAD4, SNAI1 and probably NFKB2 (PubMed:10835356, PubMed:11238952, PubMed:14681206, PubMed:14603323). SCF(BTRC) mediates the ubiquitination of NFKBIA, NFKBIB and NFKBIE; the degradation frees the associated NFKB1 to translocate into the nucleus and to activate transcription (PubMed:10066435, PubMed:10497169, PubMed:10644755). Ubiquitination of NFKBIA occurs at 'Lys-21' and 'Lys-22' (PubMed:10066435). SCF(BTRC) mediates the ubiquitination of CEP68; this is required for centriole separation during mitosis (PubMed:25704143, PubMed:25503564). SCF(BTRC) mediates the ubiquitination and subsequent degradation of nuclear NFE2L1 (By similarity). Has an essential role in the control of the clock-dependent transcription via degradation of phosphorylated PER1 and PER2 (PubMed:15917222). May be involved in ubiquitination and subsequent proteasomal degradation through a DBB1-CUL4 E3 ubiquitin-protein ligase. Required for activation of NFKB-mediated transcription by IL1B, MAP3K14, MAP3K1, IKBKB and TNF. Required for proteolytic processing of GLI3 (PubMed:16371461). Mediates ubiquitination of REST, thereby leading to its proteasomal degradation (PubMed:21258371, PubMed:18354482). {ECO:0000250|UniProtKB:Q3ULA2, ECO:0000269|PubMed:10066435, ECO:0000269|PubMed:10497169, ECO:0000269|PubMed:10644755, ECO:0000269|PubMed:10835356, ECO:0000269|PubMed:11238952, ECO:0000269|PubMed:11359933, ECO:0000269|PubMed:11994270, ECO:0000269|PubMed:12077367, ECO:0000269|PubMed:12791267, ECO:0000269|PubMed:12820959, ECO:0000269|PubMed:12902344, ECO:0000269|PubMed:14603323, ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:14988407, ECO:0000269|PubMed:15448698, ECO:0000269|PubMed:15917222, ECO:0000269|PubMed:16371461, ECO:0000269|PubMed:18354482, ECO:0000269|PubMed:21258371, ECO:0000269|PubMed:22087322, ECO:0000269|PubMed:25503564, ECO:0000269|PubMed:25704143, ECO:0000269|PubMed:9859996}.

Q9NWT6

Main function of 5'-partner protein: FUNCTION: Hydroxylates HIF-1 alpha at 'Asn-803' in the C-terminal transactivation domain (CAD). Functions as an oxygen sensor and, under normoxic conditions, the hydroxylation prevents interaction of HIF-1 with transcriptional coactivators including Cbp/p300-interacting transactivator. Involved in transcriptional repression through interaction with HIF1A, VHL and histone deacetylases. Hydroxylates specific Asn residues within ankyrin repeat domains (ARD) of NFKB1, NFKBIA, NOTCH1, ASB4, PPP1R12A and several other ARD-containing proteins. Also hydroxylates Asp and His residues within ARDs of ANK1 and TNKS2, respectively. Negatively regulates NOTCH1 activity, accelerating myogenic differentiation. Positively regulates ASB4 activity, promoting vascular differentiation. {ECO:0000269|PubMed:12042299, ECO:0000269|PubMed:12080085, ECO:0000269|PubMed:17003112, ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:18299578, ECO:0000269|PubMed:19245366, ECO:0000269|PubMed:21177872, ECO:0000269|PubMed:21251231}.
Ensembl transtripts involved in fusion geneENST idsENST00000370187, ENST00000393441, 
ENST00000408038, ENST00000493877, 
ENST00000528044, ENST00000299163, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score9 X 5 X 8=3604 X 3 X 3=36
# samples 94
** MAII scorelog2(9/360*10)=-2
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/36*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: BTRC [Title/Abstract] AND HIF1AN [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: BTRC [Title/Abstract] AND HIF1AN [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)BTRC(103190209)-HIF1AN(102296168), # samples:2
Anticipated loss of major functional domain due to fusion event.BTRC-HIF1AN seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BTRC-HIF1AN seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BTRC-HIF1AN seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BTRC-HIF1AN seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneBTRC

GO:0000209

protein polyubiquitination

12820959

HgeneBTRC

GO:0006511

ubiquitin-dependent protein catabolic process

15448698

HgeneBTRC

GO:0016567

protein ubiquitination

16885022|18354482

HgeneBTRC

GO:0042752

regulation of circadian rhythm

15917222

HgeneBTRC

GO:0043161

proteasome-mediated ubiquitin-dependent protein catabolic process

15917222

TgeneHIF1AN

GO:0036138

peptidyl-histidine hydroxylation

21251231

TgeneHIF1AN

GO:0042264

peptidyl-aspartic acid hydroxylation

21177872

TgeneHIF1AN

GO:0042265

peptidyl-asparagine hydroxylation

12080085|12215170|14734545|21177872

TgeneHIF1AN

GO:0045663

positive regulation of myoblast differentiation

18299578

TgeneHIF1AN

GO:0045746

negative regulation of Notch signaling pathway

18299578

TgeneHIF1AN

GO:0055114

oxidation-reduction process

12080085|12215170

TgeneHIF1AN

GO:0061428

negative regulation of transcription from RNA polymerase II promoter in response to hypoxia

11641274



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:103190209/chr10:102296168)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across BTRC (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across HIF1AN (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000370187BTRCchr10103190209+ENST00000299163HIF1ANchr10102296168+13008274641146360
ENST00000393441BTRCchr10103190209+ENST00000299163HIF1ANchr10102296168+12969235251107360

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000370187ENST00000299163BTRCchr10103190209+HIF1ANchr10102296168+0.0002702540.9997297
ENST00000393441ENST00000299163BTRCchr10103190209+HIF1ANchr10102296168+0.0002689550.999731

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for BTRC-HIF1AN

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
BTRCchr10103190209HIF1ANchr1010229616823570LYNPGTGALTAFQEPVVLTDTNLVYP
BTRCchr10103190209HIF1ANchr1010229616827470LYNPGTGALTAFQEPVVLTDTNLVYP

Top

Potential FusionNeoAntigen Information of BTRC-HIF1AN in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BTRC-HIF1AN_103190209_102296168.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:02TAFQEPVV0.99950.9511917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:01TAFQEPVV0.99940.9489917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B52:01TAFQEPVV0.99910.997917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:22ALTAFQEPV0.99650.8292716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:60ALTAFQEPV0.99590.7842716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:11ALTAFQEPV0.99590.8185716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:13ALTAFQEPV0.99550.84716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:27ALTAFQEPV0.99510.7665716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:38ALTAFQEPV0.99450.7475716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:16ALTAFQEPV0.99430.7263716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:08TAFQEPVVL0.99360.9665918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:03TAFQEPVVL0.99090.9677918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:01TAFQEPVVL0.98620.9696918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:19ALTAFQEPV0.98430.6233716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:02TAFQEPVVL0.98390.8199918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:18TAFQEPVVL0.98020.9355918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:02TAFQEPVVL0.9760.9925918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:04TAFQEPVVL0.9760.9925918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:10TAFQEPVVL0.97330.8895918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:05TAFQEPVVL0.9720.9254918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B14:02TAFQEPVVL0.97120.8661918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B14:01TAFQEPVVL0.97120.8661918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:37TAFQEPVVL0.97060.8778918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:35ALTAFQEPV0.95980.8004716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:01TAFQEPVVL0.95950.8253918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B52:01TAFQEPVVL0.95790.9975918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B53:01TAFQEPVVL0.95210.8571918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:16TAFQEPVVL0.94490.9835918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B48:01TAFQEPVVL0.90930.925918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B39:24TAFQEPVVL0.88730.749918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B81:01TAFQEPVVL0.84130.8377918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B39:01TAFQEPVVL0.82190.9666918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B46:01TAFQEPVVL0.81460.7525918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B39:13TAFQEPVVL0.63540.9729918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B13:01TAFQEPVVL0.43130.9955918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:16ALTAFQEPVVL0.90340.7119718
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:67ALTAFQEPVVL0.89450.7699718
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:24ALTAFQEPVVL0.89450.7699718
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:30ALTAFQEPVVL0.89450.7699718
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:29ALTAFQEPVVL0.84560.7716718
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:07TAFQEPVV0.99930.9962917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B78:01TAFQEPVV0.99870.9527917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C04:07AFQEPVVL0.99430.971018
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:08TAFQEPVV0.99410.8457917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C04:10AFQEPVVL0.99390.96461018
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C04:14AFQEPVVL0.9610.97231018
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:07TAFQEPVVL0.99970.988918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:19TAFQEPVVL0.99960.9951918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:08TAFQEPVVL0.99960.98918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C15:04TAFQEPVVL0.99950.9232918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C15:06TAFQEPVVL0.99930.9499918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C04:06TAFQEPVVL0.99730.9694918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:02ALTAFQEPV0.99660.7805716
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C08:04TAFQEPVVL0.99420.9763918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C08:13TAFQEPVVL0.99420.9763918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:21TAFQEPVVL0.99010.9683918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B56:04TAFQEPVVL0.98080.6456918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:12TAFQEPVVL0.9760.9925918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:07TAFQEPVVL0.9610.9962918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C12:12TAFQEPVVL0.95190.9642918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B14:03TAFQEPVVL0.94760.8756918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C08:03TAFQEPVVL0.93580.9918918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B39:08TAFQEPVVL0.93450.9447918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C01:30TAFQEPVVL0.93140.971918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C12:16TAFQEPVVL0.92810.9694918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:13TAFQEPVVL0.91970.9579918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C02:06TAFQEPVVL0.91460.972918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B78:01TAFQEPVVL0.91450.8443918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:14TAFQEPVVL0.91120.9862918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:05TAFQEPVVL0.88480.9901918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:29TAFQEPVVL0.87760.963918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B39:09TAFQEPVVL0.8740.87918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:27TAFQEPVVL0.86590.9736918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C06:03TAFQEPVVL0.860.9916918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C12:04TAFQEPVVL0.85610.9889918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:08TAFQEPVVL0.85520.7655918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:19TAFQEPVVL0.85320.9033918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B39:10TAFQEPVVL0.83370.9734918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:95TAFQEPVVL0.82230.8971918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C01:17TAFQEPVVL0.73710.973918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C08:15TAFQEPVVL0.72130.9821918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B39:05TAFQEPVVL0.58830.9635918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B48:03TAFQEPVVL0.40560.7299918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-A02:01ALTAFQEPVVL0.89450.7699718
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:13TAFQEPVV0.99940.8649917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B78:02TAFQEPVV0.99930.9555917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:14TAFQEPVV0.99930.9303917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:09TAFQEPVV0.99810.9259917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:21TAFQEPVV0.99730.9202917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:29TAFQEPVV0.9950.7811917
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C04:01AFQEPVVL0.99430.971018
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C18:01AFQEPVVL0.99240.96811018
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C04:04AFQEPVVL0.98190.98771018
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C14:02AFQEPVVL0.9610.97981018
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C14:03AFQEPVVL0.9610.97981018
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:03TAFQEPVVL0.99970.9948918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:04TAFQEPVVL0.99970.9948918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C15:09TAFQEPVVL0.99950.9232918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:05TAFQEPVVL0.99950.9718918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:17TAFQEPVVL0.99950.9853918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:67TAFQEPVVL0.99940.9932918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:02TAFQEPVVL0.99910.9873918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C15:05TAFQEPVVL0.99910.9522918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C15:02TAFQEPVVL0.99890.927918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C16:04TAFQEPVVL0.99680.9785918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C04:04TAFQEPVVL0.99560.9737918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:11TAFQEPVVL0.99170.9679918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C03:06TAFQEPVVL0.98640.9951918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:13TAFQEPVVL0.98640.9704918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:77TAFQEPVVL0.98620.9696918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:23TAFQEPVVL0.98550.9718918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B56:02TAFQEPVVL0.98080.6456918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:05TAFQEPVVL0.97970.5867918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:20TAFQEPVVL0.97820.9914918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:09TAFQEPVVL0.9760.9925918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:22TAFQEPVVL0.97580.7663918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:28TAFQEPVVL0.96940.99918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:30TAFQEPVVL0.96860.9503918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:17TAFQEPVVL0.96860.9503918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:06TAFQEPVVL0.96750.8127918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:14TAFQEPVVL0.96170.8225918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C12:03TAFQEPVVL0.96130.9777918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:13TAFQEPVVL0.95820.7481918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:04TAFQEPVVL0.9570.9589918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B78:02TAFQEPVVL0.95210.845918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C12:02TAFQEPVVL0.9510.9702918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:24TAFQEPVVL0.9470.9625918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C06:06TAFQEPVVL0.94290.9848918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C08:01TAFQEPVVL0.93580.9918918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:17TAFQEPVVL0.91790.9712918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:22TAFQEPVVL0.91710.8881918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:09TAFQEPVVL0.9120.7876918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C16:01TAFQEPVVL0.89640.9757918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C02:10TAFQEPVVL0.89480.9803918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C02:02TAFQEPVVL0.89480.9803918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:29TAFQEPVVL0.89350.6659918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B53:02TAFQEPVVL0.89120.8706918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C16:02TAFQEPVVL0.88580.9878918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B51:21TAFQEPVVL0.88260.7926918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C06:02TAFQEPVVL0.86650.9887918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C06:17TAFQEPVVL0.86650.9887918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:09TAFQEPVVL0.85890.9731918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C06:08TAFQEPVVL0.85620.9895918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C17:01TAFQEPVVL0.8480.9748918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:73TAFQEPVVL0.82860.9838918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B39:02TAFQEPVVL0.82580.9742918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B07:13TAFQEPVVL0.82370.8789918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C07:01TAFQEPVVL0.81380.8954918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:30TAFQEPVVL0.79920.9773918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B08:12TAFQEPVVL0.77740.9487918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C01:02TAFQEPVVL0.73990.9715918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C01:03TAFQEPVVL0.73720.9673918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-C08:02TAFQEPVVL0.72130.9821918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:11TAFQEPVVL0.7090.9367918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B15:08TAFQEPVVL0.70720.9353918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:43TAFQEPVVL0.70270.9378918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B48:05TAFQEPVVL0.70110.5082918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B40:12TAFQEPVVL0.40560.7299918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B40:21TAFQEPVVL0.36190.8317918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B18:07TAFQEPVVL0.12290.9108918
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:13LTAFQEPVVL0.77390.9596818
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B35:13ALTAFQEPVVL0.74220.9638718
BTRC-HIF1ANchr10103190209chr10102296168274HLA-B40:21ALTAFQEPVVL0.62560.9326718

Top

Potential FusionNeoAntigen Information of BTRC-HIF1AN in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BTRC-HIF1AN_103190209_102296168.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0301FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0310FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0313FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0315FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0318FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0320FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0322FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0326FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0328FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0330FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0332FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0334FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0336FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0338FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0342FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0344FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0346FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0348FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0350FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0352FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0354FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0422FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0444FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0469FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0469AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0478FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0479FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0701FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0703FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0704FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0705FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0706FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0707FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0708FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0709FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0711FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0712FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0713FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0714FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0715FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0716FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0717FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0719FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0819FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0825FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0834FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-0906FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1117FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1152FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1401FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1404FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1404AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1405FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1407FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1408FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1410FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1410AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1411FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1423FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1426FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1428FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1428AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1431FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1432FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1435FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1438FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1439FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1439AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1443FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1445FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1448FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1449FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1450FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1450AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1454FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1455FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1456FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1458FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1459FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1460FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1461FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1461AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1462FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1468FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1470FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1471FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1471AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1475FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1475AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1476FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1479FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1482FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1482AFQEPVVLTDTNLVY1025
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1486FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1487FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1488FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1490FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1491FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1493FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1496FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1497FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1499FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1503TGALTAFQEPVVLTD520
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1503GTGALTAFQEPVVLT419
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1503GALTAFQEPVVLTDT621
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1512TGALTAFQEPVVLTD520
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1523TGALTAFQEPVVLTD520
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1523GTGALTAFQEPVVLT419
BTRC-HIF1ANchr10103190209chr10102296168274DRB1-1525FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0101FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0104FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0105FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0108FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0111FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0112FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0113FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0114FQEPVVLTDTNLVYP1126
BTRC-HIF1ANchr10103190209chr10102296168274DRB3-0301FQEPVVLTDTNLVYP1126

Top

Fusion breakpoint peptide structures of BTRC-HIF1AN

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2660GALTAFQEPVVLTDBTRCHIF1ANchr10103190209chr10102296168274

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BTRC-HIF1AN

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2660GALTAFQEPVVLTD-7.15543-7.26883
HLA-B14:023BVN2660GALTAFQEPVVLTD-4.77435-5.80965
HLA-B52:013W392660GALTAFQEPVVLTD-6.80875-6.92215
HLA-B52:013W392660GALTAFQEPVVLTD-4.20386-5.23916
HLA-A11:014UQ22660GALTAFQEPVVLTD-7.5194-8.5547
HLA-A11:014UQ22660GALTAFQEPVVLTD-6.9601-7.0735
HLA-A24:025HGA2660GALTAFQEPVVLTD-7.52403-7.63743
HLA-A24:025HGA2660GALTAFQEPVVLTD-5.82433-6.85963
HLA-B27:056PYJ2660GALTAFQEPVVLTD-3.28285-4.31815
HLA-B44:053DX82660GALTAFQEPVVLTD-5.91172-6.94702
HLA-B44:053DX82660GALTAFQEPVVLTD-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of BTRC-HIF1AN

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
BTRC-HIF1ANchr10103190209chr101022961681018AFQEPVVLGCTTTCCAGGAGCCTGTGGTGCTG
BTRC-HIF1ANchr10103190209chr10102296168716ALTAFQEPVGCACTCACAGCTTTCCAGGAGCCTGTG
BTRC-HIF1ANchr10103190209chr10102296168718ALTAFQEPVVLGCACTCACAGCTTTCCAGGAGCCTGTGGTGCTG
BTRC-HIF1ANchr10103190209chr10102296168818LTAFQEPVVLCTCACAGCTTTCCAGGAGCCTGTGGTGCTG
BTRC-HIF1ANchr10103190209chr10102296168917TAFQEPVVACAGCTTTCCAGGAGCCTGTGGTG
BTRC-HIF1ANchr10103190209chr10102296168918TAFQEPVVLACAGCTTTCCAGGAGCCTGTGGTGCTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
BTRC-HIF1ANchr10103190209chr101022961681025AFQEPVVLTDTNLVYGCTTTCCAGGAGCCTGTGGTGCTGACCGACACAAATCTTGTGTAT
BTRC-HIF1ANchr10103190209chr101022961681126FQEPVVLTDTNLVYPTTCCAGGAGCCTGTGGTGCTGACCGACACAAATCTTGTGTATCCT
BTRC-HIF1ANchr10103190209chr10102296168419GTGALTAFQEPVVLTGGGACTGGCGCACTCACAGCTTTCCAGGAGCCTGTGGTGCTGACC
BTRC-HIF1ANchr10103190209chr10102296168520TGALTAFQEPVVLTDACTGGCGCACTCACAGCTTTCCAGGAGCCTGTGGTGCTGACCGAC
BTRC-HIF1ANchr10103190209chr10102296168621GALTAFQEPVVLTDTGGCGCACTCACAGCTTTCCAGGAGCCTGTGGTGCTGACCGACACA

Top

Information of the samples that have these potential fusion neoantigens of BTRC-HIF1AN

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
KIRCBTRC-HIF1ANchr10103190209ENST00000370187chr10102296168ENST00000299163TCGA-BP-5202-01A

Top

Potential target of CAR-T therapy development for BTRC-HIF1AN

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to BTRC-HIF1AN

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to BTRC-HIF1AN

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource